Insmed Incorporated (INSM) earnings on October 29, 2026
More Insmed Incorporated earnings
Prior outlook: Optimistic Outcome: Accurate
INSM soared 21.76% intraday after strong results and closed 15.06% higher, joining a broad rise in smaller healthcare stocks.
INSM price around the earnings
111.59
Change: +15.1%
2026-10-29, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Accurate
- Thesis published
- Results released
The scenario for the price is optimistic and outweighs cautious news and crowd sentiment. Analysts cite strong price targets alongside modest growth expectations, although recent price weakness and mixed earnings reactions keep the outlook from looking one-sided.
Context analyzed before publication
- Playbook
- Recent underperformance contrasts with strong analyst targets and favorable past earnings. Price volatility tends to be high, and recent price moves have been substantial.
- Trend
- Analyst optimism peaked, then softened
Analysts
Drivers
-
Analysts
Positive
Across 22 analyst opinions, a strongly positive rating points to a $196 target, 102.2% above the reference price.
Evidence
- Analyst consensus
- Strong buy
- Consensus average (1-5)
- 1.29
- Analysts covering the stock
- 22
- Average price target
- 196.14
- Lowest price target
- 165
- Highest price target
- 243
- Upside to price target
- 102.2%
- Revenue growth
- 296.1%
- Forward EPS
- 0.79
- Trailing EPS
- -4.1
- Analyst moves in the last 60 days
- 5
- Strong buy: 5
- Buy: 18
- Hold: 1
- Sell: 0
- Strong sell: 0
- Strong buy
- 5
- Buy
- 18
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
- October 21, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
- October 12, 2026 · Wolfe Research: Downgrades rating (Outperform → Peer Perform)
- October 12, 2026 · HC Wainwright & Co.: Reiterates rating (Buy → Buy)
- September 30, 2026 · Barclays: Maintains rating (Overweight → Overweight)
- September 15, 2026 · Roth Capital: Reiterates rating (Buy → Buy)
News and sentiment
Drivers
-
News & sentiment
Negative
Morgan Stanley maintained a positive rating but reduced its target to $213, while public sentiment remains fully optimistic.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
- Messages
- 30
News
Sources (9)
- $100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today (opens in a new tab) — Benzinga
- Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $213 (opens in a new tab) — Benzinga
- Top 3 Health Care Stocks That Could Blast Off In October (opens in a new tab) — Benzinga
- Insmed Appoints Paul Hudson and Utpal Koppikar to Board of Directors (opens in a new tab) — fiscal.ai
- Insmed Launches BRINSUPRI® Tablets in Japan for Non-Cystic Fibrosis Bronchiectasis (opens in a new tab) — fiscal.ai
- This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday (opens in a new tab) — Benzinga
- Wolfe Research Downgrades Insmed to Peer Perform (opens in a new tab) — Benzinga
- HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target (opens in a new tab) — Benzinga
- $100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today (opens in a new tab) — Benzinga
Technicals
Drivers
-
Technical
Negative
The 30-day return was -17.44%, while SPY gained 0.89%. Performance relative to the broader market was also weak, but the scenario points optimistic.
Evidence
- Price when the context was analyzed
- 97.17
- Average true range (ATR)
- 3.2%
- Distance to 52-week high
- -54.1%
- 14-day change (14d)
- -0.7%
- 30-day change (30d)
- -17.4%
- 30-day relative strength
- -18.3%
- SPY change (30d)
- +0.9%
- Nearest support
- 96.53
- Distance to nearest support
- 0.7%
- Nearest resistance
- 97.21
- Distance to nearest resistance
- 0%
- Volume accumulation ratio (14d / 46d)
- 1.24
- Mid: 96.53 (0.7% away, 0.2 ATR, 16 touches)
- Minor: 95.4 (1.8% away, 0.57 ATR, 8 touches)
- Minor: 93.95 (3.3% away, 1.03 ATR, 9 touches)
- Mid: 97.21 (0% away, 0.01 ATR, 13 touches)
- Mid: 97.87 (0.7% away, 0.23 ATR, 15 touches)
- Mid: 99.02 (1.9% away, 0.6 ATR, 16 touches)
Trends
Evidence
- Average earnings surprise
- +13.9%
- August 6, 2026: actual EPS -0.06 vs estimate -0.68 (surprise +91.2%)
- May 7, 2026: actual EPS -0.76 vs estimate -1 (surprise +23.9%)
- February 19, 2026: actual EPS -1.54 vs estimate -1.17 (surprise -31.9%)
- October 30, 2025: actual EPS -1.75 vs estimate -1.37 (surprise -27.8%)
Expected move
Drivers
-
Past earnings
Positive
August earnings per share beat estimates by 91.2%. The price then jumped 30.0% and continued another 34.2%.
- Implied move
- +4.5%
- Source
- Options chain
Reactions over its last 21 earnings
- Median move
- 2.4%
- 75th percentile move
- 6.3%
- 90th percentile move
- 16.6%
- Up / down moves
- 11 / 10
- Average up move
- +8.3%
- Average down move
- -4.8%
Monitoring and close
What Insmed Incorporated reported
- Status
- Finished
| Actual EPS | -0.46 |
|---|---|
| EPS estimate | -0.43 |
| EPS surprise | -7.0% |
| Revenue | $524 million |
| Revenue estimate | $501 million |
| Revenue surprise | +4.6% |
Insmed appeared among premarket gainers after strong earnings and raised guidance, while Alphabet fell 11.8% and small-cap stocks rallied as GDP growth beat expectations.
Sources (7)
- Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday (opens in a new tab) — Benzinga
- Premarket Gainers and Losers on Oct. 29, 2026 (opens in a new tab) — ChartMill
- Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update (opens in a new tab) — fiscal.ai
- Insmed reported a loss of $0.46 per share, below the $0.43 estimate, and sales of $524.428 million, above the $501.350 million estimate. — Benzinga
- Insmed Q3 EPS $(0.46) Misses $(0.43) Estimate, Sales $524.428M Beat $501.350M Estimate (opens in a new tab) — Benzinga
- Insmed Raises FY2026 Sales Guidance from $1.700B-$1.870B to $1.810B-$1.870B vs $1.801B Est (opens in a new tab) — Benzinga
- Insmed Incorporated 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) — SeekingAlpha
Pre-market second reading after the results
- Verdict
- Missed expectations
Heading into the open, Results beat expectations on revenue but not on earnings and the price is indicating +13.4% pre-market, a move 6x the stock's usual reaction (about 2%). The figures confirm the optimistic scenario. Across our market history, in the 461 similar cases the close held that direction 94% of the time.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- +15.1%
- Max favorable move (MFE)
- 21.8%
- Max adverse move (MAE)
- 1.3%